Hypofractionated stereotactic re-irradiation for progressive glioblastoma: twelve years’ experience of a single center
Journal of Neuro-Oncology · 2024
DOI: 10.1007/s11060-024-04607-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Neuro-Oncology, 2024. Verfasst von Melek Tugce Yilmaz und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Hacettepe University Faculty of Medicine, Ankara, Turkey. Hauptthemen laut MEDLINE: Glioblastoma, Brain Neoplasms, Re-Irradiation, Radiosurgery. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hacettepe University.
Abstract (Originalsprache)
Purpose
We aimed to evaluate the prognostic factors and the role of stereotactic radiotherapy (SRT) as a re-irradiation technique in the management of progressive glioblastoma.
Methods
The records of 77 previously irradiated glioblastoma patients who progressed and received second course hypofractionated SRT (1–5 fractions) between 2009 and 2022 in our department were evaluated retrospectively. Statistical Package for the Social Sciences (SPSS) version 23.0 (IBM, Armonk, NY, USA) was utilized for all statistical analyses.
Results
The median time to progression from the end of initial radiotherapy was 14 months (range, 6–68 months). The most common SRT schedule was 30 Gy (range, 18–50 Gy) in 5 fractions (range, 1–5 fractions). The median follow-up after SRT was 9 months (range, 3–80 months). One-year overall (OS) and progression-free survival (PFS) rates after SRT were 46% and 35%, respectively. Re-irradiation dose and the presence of pseudoprogression were both significant independent positive prognostic factors for both OS ( p = 0.009 and p = 0.04, respectively) and PFS ( p = 0.008 and p = 0.04, respectively). For PFS, progression-free interval > 14 months was also a prognostic factor ( p = 0.04). The treatment was well tolerated without significant acute toxicity. During follow-up, radiation necrosis was observed in 17 patients (22%), and 14 (82%) of them were asymptomatic.
Conclusion
Hypofractionated SRT is an effective treatment approach for patients with progressive glioblastoma. Younger patients who progressed later than 14 months, received higher SRT doses, and experienced pseudoprogression following SRT had improved survival rates.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology, Hacettepe University Faculty of Medicine, Ankara, Turkey.
- Department of Radiation Oncology, Hacettepe University Faculty of Medicine, Ankara, Turkey. yazicig@gmail.com.
- Department of Medical Oncology, Hacettepe University Faculty of Medicine, Ankara, Turkey.
- Radiology Department, Hacettepe University Faculty of Medicine, Ankara, Turkey.
Förderung
- Hacettepe University
Zitieren
APA
Yilmaz, M. T., Kahvecioglu, A., Yazici, G., Mohammadipour, S., Kertmen, N., Cifci, G. C., & Zorlu, F. (2024). Hypofractionated stereotactic re-irradiation for progressive glioblastoma: twelve years’ experience of a single center. Journal of Neuro-Oncology. https://doi.org/10.1007/s11060-024-04607-4
Vancouver
Yilmaz MT, Kahvecioglu A, Yazici G, Mohammadipour S, Kertmen N, Cifci GC, et al. Hypofractionated stereotactic re-irradiation for progressive glioblastoma: twelve years’ experience of a single center. Journal of Neuro-Oncology. 2024. doi:10.1007/s11060-024-04607-4
BibTeX
@article{Yilmaz2024,
author = {Yilmaz, Melek Tugce and Kahvecioglu, Alper and Yazici, Gozde and Mohammadipour, Sepideh and Kertmen, Neyran and Cifci, Gokcen Coban and Zorlu, Faruk},
title = {Hypofractionated stereotactic re-irradiation for progressive glioblastoma: twelve years’ experience of a single center},
journal = {Journal of Neuro-Oncology},
year = {2024},
doi = {10.1007/s11060-024-04607-4}
}
EUVIMED